PPHLN1 Antibody
Description
Introduction to PPHLN1 and Its Antibodies
Periphilin-1 (PPHLN1), also known as CDC7 expression repressor and Gastric cancer antigen Ga50, is a ubiquitously expressed protein that plays critical roles in multiple cellular processes. The protein is encoded by the PPHLN1 gene (Gene ID: 51535) and is recognized for its involvement in the HUSH (Human Silencing Hub) complex, a multiprotein assembly that mediates epigenetic repression . PPHLN1 antibodies are immunological reagents specifically designed to detect, isolate, and characterize the Periphilin-1 protein across various experimental applications, including Western blotting, immunohistochemistry, and immunofluorescence techniques . These antibodies have become essential tools for researchers investigating epigenetic regulation, transcriptional silencing, cell cycle control, and various disease mechanisms.
Significance in Research and Clinical Applications
PPHLN1 antibodies enable detailed examination of protein expression, localization, and interaction patterns across diverse tissue types and cellular conditions. This capability is particularly valuable given PPHLN1's ubiquitous tissue distribution and multiple functions in cellular processes ranging from epigenetic regulation to epithelial differentiation . The development of highly specific PPHLN1 antibodies has facilitated significant advances in understanding the protein's role in normal biological functions and pathological conditions, including cancer research where PPHLN1 fusion proteins have demonstrated oncogenic potential .
Protein Structure and Domains
PPHLN1 contains a distinctive C-terminal region with a coiled-coil domain featuring seven heptad repeats, with the C-terminal 25 residues being sufficient for self-dimerization . This structural feature is functionally significant, particularly in the context of fusion proteins where PPHLN1's dimerization capability can drive ligand-independent activation of fusion partners . The protein undergoes post-translational modifications, serving as a substrate for transglutaminase in vitro . Notably, Western blot analyses reveal multiple observed band sizes (35, 40, 53, 55, 85, and 100 kDa) compared to the predicted band size of 53 kDa, suggesting the existence of multiple isoforms or post-translational modifications .
Cellular Localization Patterns
PPHLN1 exhibits distinctive localization patterns that vary depending on cellular differentiation states. In undifferentiated keratinocytes, PPHLN1 predominantly localizes to nuclear granules, whereas upon keratinocyte differentiation, it colocalizes with periplakin at the cell periphery and cell-cell junctions, eventually becoming incorporated into the cornified cell envelope . This dynamic localization pattern reflects PPHLN1's multifunctional nature and involvement in various cellular processes including epithelial differentiation and epidermal barrier formation .
Functional Roles of PPHLN1 Protein
PPHLN1 participates in multiple cellular functions, with its primary role centered around epigenetic regulation and transcriptional control through the HUSH complex.
PPHLN1 in Epigenetic Regulation
As a component of the HUSH complex, PPHLN1 is recruited to genomic loci enriched in H3K9me3 (trimethylated histone H3 at lysine 9) where it maintains transcriptional silencing . This maintenance function operates through promoting the recruitment of SETDB1, a histone methyltransferase that mediates further deposition of H3K9me3, thereby reinforcing transcriptional repression . Within the HUSH complex, PPHLN1 specifically contributes to the maintenance of the complex at chromatin, serving as a critical structural and functional component of this epigenetic regulatory machinery .
Role in Cell Cycle Regulation
PPHLN1 acts as a transcriptional corepressor that regulates the cell cycle, likely functioning through the HUSH complex . This regulatory role positions PPHLN1 as an important factor in controlling cellular proliferation and division, with potential implications for cancer biology and therapeutic approaches targeting cell cycle dysregulation .
Involvement in Antiviral Defense
The HUSH complex, including PPHLN1, participates in the silencing of unintegrated retroviral DNA . Following viral infection, some retroviral DNA remains unintegrated in the host genome and is transcriptionally repressed by the HUSH complex, suggesting a role for PPHLN1 in cellular defense mechanisms against viral pathogens .
Function in Epithelial Differentiation
PPHLN1 contributes to epithelial differentiation by promoting epidermal integrity and barrier formation . This function aligns with observations regarding PPHLN1's localization changes during keratinocyte differentiation, where it transitions from nuclear granules to cell-cell junctions, supporting its role in maintaining epithelial tissue organization and function .
Antibody Validation Methods
Commercial PPHLN1 antibodies undergo various validation procedures to ensure specificity and reactivity. For instance, Abcam's ab69569 antibody has been validated through Western blot analysis using extracts from COLO and 293 cells, with specificity confirmed through competitive inhibition with the immunizing peptide . Similarly, immunohistochemistry analyses demonstrate specific staining of human liver carcinoma tissue, with signal ablation observed when the antibody is preincubated with the immunizing peptide . Such validation protocols are essential for establishing antibody reliability and minimizing false-positive or false-negative results in research applications.
Applications of PPHLN1 Antibodies in Research
PPHLN1 antibodies serve diverse experimental applications, enabling researchers to investigate various aspects of PPHLN1 biology and function.
Western Blotting (WB)
Western blotting represents one of the primary applications for PPHLN1 antibodies, allowing detection and quantification of PPHLN1 protein in cell and tissue lysates . Western blot analyses with PPHLN1 antibodies have revealed multiple band sizes (35, 40, 53, 55, 85, and 100 kDa), suggesting complex processing or isoform expression of PPHLN1 . Typical working dilutions for Western blotting range from 1:500 to 1:2000, depending on the specific antibody and sample type .
Immunohistochemistry (IHC)
PPHLN1 antibodies enable visualization of protein expression and localization in tissue sections through immunohistochemistry . This application provides valuable insights into PPHLN1's tissue distribution patterns and potential alterations in disease states. For optimal results, antibodies such as Abcam's ab69569 are typically used at dilutions ranging from 1:50 to 1:100 for paraffin-embedded tissue sections .
Immunofluorescence (IF)
Immunofluorescence techniques utilizing PPHLN1 antibodies allow high-resolution imaging of PPHLN1's subcellular localization and potential colocalization with other proteins . This application has been particularly informative in demonstrating PPHLN1's differential localization in undifferentiated versus differentiated keratinocytes, supporting its role in epithelial differentiation .
Additional Applications
Beyond the primary applications described above, PPHLN1 antibodies are also employed in ELISA (Enzyme-Linked Immunosorbent Assay) and ICC (Immunocytochemistry) procedures . These diverse applications collectively provide a comprehensive toolkit for investigating PPHLN1's expression, localization, interactions, and functions across various experimental contexts.
PPHLN1 in Disease Mechanisms
Research utilizing PPHLN1 antibodies has contributed to understanding PPHLN1's involvement in pathological conditions, particularly in cancer biology through fusion protein formation.
FGFR2-PPHLN1 Fusion in Intrahepatic Cholangiocarcinoma
A significant finding in cancer research involves the FGFR2-PPHLN1 fusion protein, which demonstrates potent transforming potential in driving cellular proliferation . Studies employing PPHLN1 antibodies have revealed that this fusion requires an active FGFR2-derived tyrosine kinase domain and a dimerization domain contributed by PPHLN1 . The fusion protein strongly activates canonical MAPK/ERK, JAK/STAT3, and PI3K/AKT signaling pathways, promoting cellular transformation and proliferation .
Mechanistic Insights and Therapeutic Implications
Research examining the FGFR2-PPHLN1 fusion protein has demonstrated a requirement for membrane localization for its oncogenic function . PPHLN1's dimerization domain appears to drive dimerization of the fusion protein, potentially leading to ligand-independent hyperactivation of the FGFR2 kinase domain . These mechanistic insights highlight the importance of sequencing-based, mutation-specific personalized therapeutic approaches in treating FGFR2 fusion-positive intrahepatic cholangiocarcinoma . Tyrosine kinase inhibitors such as BGJ398 and TAS-120, alone or in combination with the MEK inhibitor Trametinib, have shown heterogeneous responses in a mutation-specific manner, underscoring the need for precision medicine approaches in targeting these oncogenic fusion proteins .
Research Findings and Experimental Data
Scientific investigations utilizing PPHLN1 antibodies have generated valuable experimental data regarding PPHLN1's expression, activation, and functional significance.
Tyrosine Phosphorylation and Fusion Protein Activation
Studies examining the FGFR2-PPHLN1 fusion protein have demonstrated dramatically increased tyrosine phosphorylation compared to FGFR2 alone . Specifically, immunoblotting analyses revealed that fusion with PPHLN1 leads to near-maximal kinase activation, with only slight further increases observed when incorporating additional kinase-activating mutations . These findings highlight PPHLN1's potent effect on kinase activation within fusion protein contexts, likely mediated through PPHLN1's dimerization domain.
Membrane Association and Transforming Potential
Experimental data has established a requirement for membrane localization of the FGFR2-PPHLN1 fusion protein for its transforming activity . This functional requirement aligns with PPHLN1's natural localization patterns during epithelial differentiation, where it transitions from nuclear to peripheral cellular regions . These observations provide critical insights into the mechanisms underlying PPHLN1-containing fusion proteins' oncogenic potential and suggest potential therapeutic approaches targeting membrane localization or downstream signaling pathways.
Current Limitations and Challenges
Despite the valuable insights provided by currently available PPHLN1 antibodies, certain limitations persist. The detection of multiple unexpected band sizes in Western blotting suggests complex processing or isoform expression that remains incompletely characterized . Additionally, while several antibodies target different regions of PPHLN1, comprehensive epitope mapping and comparative performance analyses across all commercially available PPHLN1 antibodies would enhance researcher ability to select optimal reagents for specific applications.
Future Research Directions
Future research utilizing PPHLN1 antibodies could explore several promising directions, including more detailed characterization of PPHLN1's role in the HUSH complex, investigation of potential therapeutic approaches targeting PPHLN1-containing fusion proteins in cancer, and examination of PPHLN1's functions in different tissue types and developmental stages. Additionally, the development of more specific monoclonal antibodies targeting distinct PPHLN1 domains or isoforms could enhance research capabilities and potentially lead to diagnostic applications in pathological conditions involving PPHLN1 dysregulation.
Product Specs
Target Background
- An analysis of FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. PMID: 25608663
- This study identified the HUSH (human silencing hub) complex, composed of three poorly characterized proteins: TASOR, MPP8, and periphilin. Notably, this complex is absent in Drosophila but is conserved from fish to humans. PMID: 26022416
- Data indicate that periphilin exhibits an overlapping expression pattern with synphilin-1 in cellular and animal models and in Lewy bodies of Parkinson's disease (PD) patients, supporting a potential role for periphilin in PD. PMID: 19730898
- Periphilin is potentially involved in epithelial differentiation and contributes to epidermal integrity and barrier formation. PMID: 12853457
- CR (periphilin) delays S-phase progression by modulating the expression of Cdc7 and other genes involved in DNA replication progression. PMID: 15474462
Q&A
What is PPHLN1 and what cellular functions does it regulate?
PPHLN1 (Periphilin-1) is a component of the Human Silencing Hub (HUSH) complex that mediates epigenetic repression. It functions as a transcriptional corepressor and regulates cell cycle progression . The protein has a calculated molecular weight of 52.7 kDa, though it typically appears at approximately 72 kDa in Western blots due to post-translational modifications .
PPHLN1 contributes to maintaining the HUSH complex at chromatin and is required for transcriptional silencing by promoting recruitment of SETDB1, a histone methyltransferase that mediates deposition of H3K9me3 marks . Additionally, PPHLN1 participates in silencing unintegrated retroviral DNA and may contribute to epithelial differentiation by supporting epidermal integrity and barrier formation .
What are the common alternative names for PPHLN1 in research literature?
PPHLN1 appears in scientific literature under several alternative designations:
Understanding these alternative nomenclatures is crucial when conducting literature searches to ensure comprehensive review of existing research.
What typical applications are PPHLN1 antibodies validated for?
PPHLN1 antibodies have been validated for multiple research applications:
| Application | Dilution Range | Notes |
|---|---|---|
| Western Blot (WB) | 1:500-1:2000 | Most commonly validated application |
| Immunohistochemistry (IHC) | 1:100-1:300 | Works on paraffin-embedded tissues |
| Immunofluorescence (IF) | 1:50-1:200 | For cellular localization studies |
| Immunocytochemistry (ICC) | 1:50-1:200 | For in vitro cell analysis |
| ELISA | 1:5000 | For quantitative protein detection |
| Chromatin Immunoprecipitation (ChIP) | Varies by antibody | For epigenetic studies |
The optimal working concentration varies among antibodies and should be determined experimentally by each researcher .
How should researchers validate PPHLN1 antibodies before experimental use?
Proper antibody validation should include:
-
Positive Control Testing: Use tissues or cell lines with known PPHLN1 expression (human or mouse tissues depending on species reactivity).
-
Knockout Validation: Compare antibody signals between wild-type and PPHLN1 knockout cells .
-
Cross-Reactivity Assessment: Test on protein arrays to ensure specificity against other proteins.
-
Application-Specific Validation: Validate separately for each intended application (WB, IHC, IF).
-
Blocking Peptide Controls: Use immunizing peptides to confirm specificity.
High-quality commercial antibodies often undergo multiple validation methods including testing against 44 normal human tissues and 20 common cancer types, plus protein array screening against hundreds of human recombinant proteins .
What species reactivity is available for PPHLN1 antibodies?
Most commercially available PPHLN1 antibodies demonstrate reactivity to:
-
Human (most common)
-
Mouse
-
Rat (less common)
Some antibodies offer cross-reactivity with multiple species based on sequence homology and conservation. When selecting antibodies for non-human studies, confirm species reactivity in product documentation .
How does PPHLN1 interact with other components of the HUSH complex?
PPHLN1 serves as a crucial interacting partner within the HUSH complex. Research reveals:
-
This association requires either TASOR or TASOR2 proteins as scaffolds, as demonstrated by co-immunoprecipitation experiments.
-
TASOR and TASOR2 exhibit mutual exclusivity in their interactions with MPP8 and PPHLN1.
-
In TASOR/TASOR2 double knockout cells, the association between PPHLN1 and MPP8 is completely abrogated.
-
PPHLN1 appears to be a limiting factor in the formation of functional HUSH complexes .
The PPHLN1-MPP8 interaction forms part of a larger network that drives heterochromatin formation at target loci, particularly at transposable elements and certain classes of genes.
What is the role of PPHLN1 in LINE-1 silencing mechanisms?
PPHLN1 plays a critical role in silencing LINE-1 retrotransposons:
-
Knockout of PPHLN1 results in marked upregulation of LINE-1 ORF1p expression, indicating derepression of LINE-1 elements .
-
PPHLN1 contributes to the stability of other HUSH complex members, as its deletion leads to reduced levels of TASOR.
-
Reintroduction of wild-type PPHLN1 transgenes effectively restores LINE-1 silencing in PPHLN1 knockout cells.
-
PPHLN1 functions as part of the canonical HUSH complex (with TASOR and MPP8) rather than the HuSH2 variant when regulating LINE-1 elements .
This regulatory role highlights PPHLN1 as a potential target for studying retrotransposon control mechanisms in human cells.
What are the key considerations for using PPHLN1 antibodies in ChIP assays?
ChIP-seq experiments with PPHLN1 antibodies require careful optimization:
-
Antibody Selection: Use ChIP-validated antibodies with demonstrated specificity for PPHLN1.
-
Cross-linking Optimization: Standard formaldehyde cross-linking (1%) for 10 minutes is typically sufficient.
-
Control Experiments: Include IgG controls and ideally PPHLN1 knockout cells as negative controls.
-
Target Verification: Canonical HUSH complex (containing PPHLN1) targets LINE-1 elements, particularly L1HS and L1PA families, while the HuSH2 complex targets distinct genomic loci .
-
Antibody Compatibility: Verify the antibody's ability to recognize cross-linked epitopes.
Based on published research, approximately 40% of HUSH ChIP peaks are located near LINE-1 elements, providing a positive control for ChIP-seq validation .
How can researchers distinguish between PPHLN1's roles in HuSH versus HuSH2 complexes?
To differentiate PPHLN1's functions in the two complex variants:
-
Sequential ChIP (Re-ChIP): First immunoprecipitate with PPHLN1 antibodies, then with either TASOR (HuSH) or TASOR2 (HuSH2) antibodies.
-
Complex-Specific Genomic Targets:
-
Competition Experiments: Overexpress tagged TASOR or TASOR2 to shift the balance of complexes, as demonstrated by research showing that overexpression of either protein reduces MPP8 levels at opposing genomic sites .
-
Functional Readouts: LINE-1 derepression occurs with TASOR knockout but not with TASOR2 knockout, providing a functional distinction between complexes .
What protein interactions should be monitored when studying PPHLN1 function?
Key protein interactions to monitor include:
| Interaction Partner | Experimental Method | Functional Significance |
|---|---|---|
| MPP8 | Co-IP, Proximity Ligation | Core HuSH/HuSH2 component |
| TASOR | Co-IP, ChIP-seq | Forms canonical HuSH complex |
| TASOR2 | Co-IP, ChIP-seq | Forms alternative HuSH2 complex |
| SETDB1 | ChIP-seq, Co-IP | Histone methyltransferase recruited by HuSH |
| Nuclear Exosome Components | Mass spectrometry, Co-IP | Associated complexes identified in IP experiments |
Monitoring these interactions provides insight into the assembly and function of PPHLN1-containing complexes .
How do PPHLN1 antibody signals compare with calculated versus observed molecular weights?
Researchers should be aware of the discrepancy between calculated and observed molecular weights when detecting PPHLN1:
-
Calculated molecular weight: 52.7 kDa
-
Observed molecular weight in Western blots: Approximately 72 kDa
This difference likely results from post-translational modifications and should be considered when interpreting Western blot results. Using positive controls with known PPHLN1 expression is recommended to identify the correct band .
What are the optimal storage conditions for PPHLN1 antibodies?
For maximum shelf life and performance:
-
Long-term storage: -20°C for up to one year
-
Working storage: 4°C for up to one month for frequent use
-
Formulation: Most antibodies are provided in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide
-
Critical precaution: Avoid repeated freeze-thaw cycles as they significantly reduce antibody efficacy
Following these storage guidelines helps maintain antibody performance across experiments.
How can researchers address specificity challenges with PPHLN1 antibodies?
To maximize specificity and reduce background:
-
Blocking optimization: Test different blocking agents (BSA vs. milk protein) to determine optimal conditions.
-
Antibody dilution series: Perform titration experiments to find the minimum effective concentration.
-
Knockout controls: Where possible, include PPHLN1 knockout samples to confirm signal specificity.
-
Peptide competition: Pre-incubate antibody with immunizing peptide to confirm binding specificity.
-
Orthogonal validation: Compare results using different antibodies targeting distinct PPHLN1 epitopes.
Some suppliers offer blocking peptides derived from the immunogen sequence (typically residues 71-120 of human PPHLN1) .
How can PPHLN1 antibodies contribute to understanding epigenetic regulation?
PPHLN1 antibodies offer valuable tools for investigating epigenetic mechanisms:
-
ChIP-seq co-occupancy analysis: Compare PPHLN1 binding with H3K9me3 marks to identify silenced regions.
-
Sequential ChIP (Re-ChIP): Combine PPHLN1 ChIP with histone modification ChIP to correlate HUSH complex localization with specific epigenetic states.
-
HUSH complex dynamics: Track changes in PPHLN1 distribution following treatments with epigenetic modulators.
-
Heterochromatin formation: Study the temporal relationship between PPHLN1 recruitment and heterochromatin establishment.
Research demonstrates that PPHLN1, through the HUSH complex, is recruited to genomic loci rich in H3K9me3 and maintains transcriptional silencing by promoting further H3K9me3 deposition via SETDB1 recruitment .
What insights have been gained about the stoichiometry of PPHLN1 in cellular complexes?
Recent research indicates:
-
MPP8 and PPHLN1 are limiting factors in the formation of HUSH complexes.
-
The canonical HUSH complex (with TASOR) appears more abundant than the HuSH2 variant (with TASOR2) in K562 cells.
-
Competition for MPP8 and PPHLN1 regulates the balance between HUSH and HuSH2 complexes.
-
Overexpression of TASOR2 can lead to derepression of LINE-1 elements by depleting available PPHLN1 from the canonical HUSH complex .
These findings reveal how cellular regulation of PPHLN1 availability influences epigenetic silencing mechanisms, suggesting potential strategies for experimental manipulation of these pathways.
